Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Bipolar Disorder (July 2020)

Posted by Matt Breese on Jul 24, 2020

Find me on:

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 23% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Bipolar Disorder-3Q2020Data snapshot as of Q3 2020

Trends: A new brand drug, Allergan plc’s Vraylar (cariprazine), for bipolar disorder will have little impact on how health plans cover these medications, experts say. Health plans will continue to encourage the use of less expensive generic bipolar drugs.  

To read the full Reality Check on Bipolar Disorder treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing